The UK and US have secured a major trade agreement that will preserve zero tariffs on British pharmaceutical products entering the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to boost expenditure on medicines through the public health system. This pledge guarantees that tariffs on these key goods will stay at nothing for a period of the next three years.
This agreement comes after earlier statements to hike tariffs on branded pharmaceutical products, with figures discussed up to double the cost.
"This agreement between the Britain reinforces the international landscape for new treatments and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement declared.
Trade Importance
Drugs are one of the the United Kingdom's largest export categories to the United States, which is clearly the largest market for major UK drugmakers.
Export figures show that in the one-year period to the end of September, the UK exported pharmaceutical products valued at billions to the US. This value represented 17.4% of total UK exports in that span.
"This agreement secures employment, boosts funding and sets the stage for the UK to become a global hub for medical research," a government official stated.
Key British Pledges
The pact involves several specific changes from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to increase overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum manufacturers must refund to the NHS to stay within budget will be limited at 15%. Previously, rebates exceeded 20%.
Industry Background
The pact takes place against a ongoing dispute between the sector and the UK government over medicine costs and NHS adoption.
The disagreement were heightened by claims that American customers were paying a premium for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or cancelled, while major funding commitments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a share of its overall budget over the past decade.
